Since miR-129-5p expression in various cancer entities (e.g., endometrial cancer, breast cancer and gastric cancer) is mediated by EZH2 [42,43,44], an epigenetic modulator of H3K27me3 and DNA methylation [45,46], we investigated if EZH2 is mediated by BRAF/MEK pathway inhibition. This evidence concerns the gene EZH2 and cancer.